

News Release

Ashland reports preliminary financial results for first quarter of fiscal year 2021

- Sales of \$552 million, up four percent from the prior-year quarter
- Net income of \$56 million, or \$0.91 per diluted share
- Income from continuing operations of \$61 million, or \$0.99 per diluted share
- Adjusted income from continuing operations excluding intangibles amortization expense of \$58 million, or \$0.94 per diluted share
- Adjusted EBITDA of \$124 million
- Cash flows provided by operating activities of \$106 million; free cash flows of \$76 million

WILMINGTON, Del., February 3, 2021 – Ashland Global Holdings Inc. (NYSE: ASH) today announced preliminary¹ financial results for the first quarter of fiscal year 2021, which ended December 31, 2020. The global specialty materials company serves customers in a wide range of consumer and industrial markets.

Ashland's financial results during the quarter reflected execution of the company's strategy, solid overall demand and the benefit of continued cost reduction. The result was improved sales and earnings, margin growth and strong free cash flow generation. Sales were approximately \$552 million, up four percent compared to the prior-year period, as growth was realized in all three of Ashland's business groups.

Net income was \$56 million compared to net income of \$32 million in the prior-year quarter. Income from continuing operations was \$61 million compared to income of \$34 million in the prior-year quarter, or \$0.99 per diluted share compared to \$0.56 in the prior-year quarter. Adjusted income from continuing operations excluding intangibles amortization expense was \$58 million compared to \$25 million in the prior-year quarter, or \$0.94 per diluted share, up from \$0.41 in the prior-year quarter. Adjusted EBITDA was \$124 million, up from \$88 million in the prior-year quarter, driven primarily by lower operating expenses, favorable mix, improved sales in all three business groups and lower selling, general, administrative and research and development ("SARD") expenses.

Cash flows provided by operating activities totaled \$106 million compared to a deficit of \$34 million in the prior-year quarter. Free cash flows totaled \$76 million compared to a deficit of \$63 million in the prior-year quarter, driven primarily by increased earnings and disciplined working capital management.

"Ashland's financial results in the first quarter reflect our progress toward demonstrating strategic discipline, consistent organic growth, margin expansion and improved free cash flow conversion," said Guillermo Novo, chairman and chief executive officer, Ashland. "Our industrial businesses continue to see strong demand recovery, and excluding specific mix actions, our core consumer businesses continue to demonstrate top-line resilience and growth. All business groups expanded margins compared to the prior-year period. Also, Ashland's free cash flow improved dramatically when compared to the prior year, reflecting the broad-based efforts by our teams to grow earnings and continue to improve working capital."

"I am pleased with the progress our team has made driving more consistent performance while delivering profitable growth and improved cash generation," continued Novo. "While the uncertainty related to the COVID-19 pandemic continues to impact global supply chains and consumer behavior, the continued progress made by our teams in the first-fiscal quarter gives me even more confidence in our ability to deliver consistent results. I look forward to sharing additional thoughts on our plans and the progress we have made during our earnings call tomorrow morning."

Reportable Segment Performance

To aid in the understanding of Ashland's ongoing business performance, the results of Ashland's reportable segments are described below on an adjusted basis. In addition, EBITDA and adjusted EBITDA are reconciled to operating income in Table 4. Free cash flow and adjusted operating income are reconciled in Table 6 and adjusted income from continuing operations, adjusted diluted earnings per share and adjusted diluted earnings per share excluding intangible amortization expense are reconciled in Table 7 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the "Use of Non-GAAP Measures" section that further describes these adjustments below.

Consumer Specialties

Sales were \$296 million, up one percent from the prior-year quarter. Foreign currency favorably impacted sales by two percent. Strong demand in most consumer end markets was nearly offset by our exit from lower-margin product lines and continued Avoca challenges, both within Personal Care and Household.

Operating income was \$44 million, compared to \$33 million in the prior-year quarter. Adjusted EBITDA was \$79 million, up 18% from the prior-year quarter, reflecting favorable mix and lower SARD expenses in both the Life Sciences and Personal Care and Household segments.

Industrial Specialties

Sales were \$231 million, up eight percent from the prior-year quarter, driven by improving global demand for architectural coatings, construction and adhesive applications. Foreign currency favorably impacted sales by two percent.

Operating income was \$22 million, compared to \$19 million in the prior-year quarter. Adjusted EBITDA was \$55 million, up 28% from the prior-year quarter, driven by favorable volumes, mix and SARD expenses.

Intermediates & Solvents

Sales were \$33 million, up 18% from the prior-year quarter, primarily reflecting normalized internal sales volumes versus prior year when there was a planned extended shutdown at the Lima, Ohio facility.

Operating income was \$2 million, up from an operating loss of \$12 million in the prior-year quarter. Adjusted EBITDA was \$5 million, up from negative \$9 million in the prior-year quarter, which included the impact of the shutdown at the Lima facility.

Unallocated & Other

Unallocated and Other expense was \$27 million, compared to \$23 million in the prior-year quarter, primarily due to higher restructuring-related expenses. Adjusted Unallocated and Other expense was \$15 million, compared to an expense of \$16 million in the prior-year quarter.

Conference Call Webcast

Ashland will host a live webcast of its first-quarter conference call with securities analysts at 9:00 a.m. ET Thursday, February 4, 2021. The webcast will be accessible through Ashland's website at http://investor.ashland.com and will include a slide presentation. Following the live event, an archived version of the webcast and supporting materials will be available for 12 months.

Use of Non-GAAP Measures

Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide Ashland's investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide disclosure on the same basis as that used by Ashland's management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland's historical operating performance and its business units and provide continuity to investors for comparability purposes. EBITDA margin and adjusted EBITDA margin are defined as EBITDA and adjusted EBITDA divided by sales for the corresponding period.

Key items, which are set forth on Table 7 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to most accurately reflect Ashland's underlying business performance and trends. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor's ability to compare financial performance between reporting periods.

Tax-specific key items, which are set forth on Table 7 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland's underlying business performance and trends.

The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Adjusted diluted earnings per share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing earnings and diluted earnings per share metrics that exclude the effect of the identified key items and tax specific key items.

Adjusted diluted earnings per share, excluding intangibles amortization expense metric enables Ashland to demonstrate the impact of non-cash intangibles amortization expense on earnings per share, in addition to key items previously mentioned. Ashland's management believes this presentation is helpful to illustrate how previous acquisitions impact applicable period results.

About Ashland

Ashland Global Holdings Inc. (NYSE: ASH) is a premier specialty materials company with a conscious and proactive mindset for sustainability. The company serves customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 4,200 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit <u>ashland.com</u> and <u>ashland.com/sustainability</u> to learn more.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance, financial condition, and expected effects of the COVID-19 pandemic on Ashland's business, as well as the economy and other future events or circumstances. These statements include but may not be limited to Ashland's expectations regarding its ability to drive sales and earnings growth and realize further cost reductions.

Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the impact of acquisitions and/or divestitures Ashland has made or may make (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); severe weather, natural disasters, public-health crises (including the current COVID-19 pandemic), cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters); the effects of the COVID-19 pandemic on the geographies in which we operate, the end markets we serve and on our supply chain and customers, and without limitation, risks and uncertainties affecting Ashland that are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. The extent and duration of the COVID-19 pandemic on our business and operations is uncertain. Factors that will influence the impact on our business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.

¹Financial results are preliminary until Ashland's Form 10-Q is filed with the SEC TM Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations: Seth A. Mrozek +1 (302) 594-5010 samrozek@ashland.com Media Relations: Carolmarie C. Brown +1 (302) 995-3158 ccbrown@ashland.com Three months ended

December 31,

Sales \$ 552 \$ 533 Cost of sales 374 380 GROSS PROFIT 178 153 Selling, general and administrative expense 106 99 Research and development expense 106 99 Research and development expense 21 21 Intangibles amortization expense 21 21 Equity and other income 5 - OPERATING INCOME 41 17 Net interest and other expense (income) (6) 10 Net income on divestitures (6) 10 Net income no divestitures 61 10 Net income on divestitures 61 10 Income trespense (benefit) 61 10 Income tax expense (benefit) 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 0.9 \$ 0.5 Income from continuing operations (0.08) (0.03) Net income \$ 0.9 \$ 0.5 Income from continuing operations		Decemb	per 31,
Cost of sales 374 380 GROSS PROFIT 178 153 Selling, general and administrative expense 106 99 Research and development expense 15 16 Intangibles amortization expense 21 21 Equity and other income 5 2 OPERATING INCOME 41 17 Net incerest and other expense (income) (6) 10 Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 61 10 Income tax expense (lenefit) 6 2 Income from Continuing Operations 61 3 Loss from discontinued operations (net of income taxes) 5 6 3 NET INCOME \$ 5 6 3 2 Income from continuing operations (0.0 0.0 <th></th> <th></th> <th></th>			
Cost of sales 374 380 GROSS PROFIT 178 153 Selling, general and administrative expense 106 99 Research and development expense 15 16 Intangibles amortization expense 21 21 Equity and other income 5 2 OPERATING INCOME 41 17 Net incerest and other expense (income) (6) 10 Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 61 10 Income tax expense (lenefit) 6 2 Income from Continuing Operations 61 3 Loss from discontinued operations (net of income taxes) 5 6 3 NET INCOME \$ 5 6 3 2 Income from continuing operations (0.0 0.0 <th>Sales</th> <th>¢ 552</th> <th>¢ 533</th>	Sales	¢ 552	¢ 533
GROSS PROFIT 178 153 Selling, general and administrative expense 106 99 Research and development expense 15 16 Intangibles amortization expense 21 21 Equity and other income 5 - OPERATING INCOME 41 17 Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 61 10 Income tax expense (benefit) - (24) INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (22) INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 0.99 \$ 0.56 32 DILUTED EARNINGS PER SHARE 10 0.03 0.03 Income from continuing operations (0.08) 0.03 0.03 Net income \$ 0.91 0.56 0.03 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61			•
Selling, general and administrative expense 106 99 Research and development expense 15 16 Intangibles amortization expense 21 21 Equity and other income 5 - OPERATING INCOME 41 17 Net increat and other expense (income) (6) 10 Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 61 1 Income tax expense (benefit) - (24) Income tax expense (benefit) - (24) Income (siscontinued operations (net of income taxes) (5) (2) NET INCOME \$ 0.99 \$ 0.56 Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.99 \$ 0.56 Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.99 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES 170 155 Personal Care and Household 126 137 </td <td></td> <td></td> <td></td>			
Research and development expense 15 16 Intangibles amortization expense 21 21 Equity and other income 5 - OPERATING INCOME 41 17 Net interest and other expense (income) (6) 10 Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 61 10 Income tax expense (benefit) - (24) INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 56 32 DILUTED EARNINGS PER SHARE 0 0 0 Income from continuing operations (0.08) 0.03 Income (loss) from discontinued operations (0.08) 0.03 Net income \$ 0.91 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 <t< td=""><td></td><td></td><td></td></t<>			
Intangibles amortization expense 21 21 Equity and other income 5 5 5 5 5 5 5 5 5	· · · · · · · · · · · · · · · · · · ·		
Equity and other income 5 - OPERATING INCOME 41 17 Net interest and other expense (income) (6) 10 Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 61 10 Income tax expense (benefit) - (24) INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 56 \$ 32 DILUTED EARNINGS PER SHARE \$ 0.99 \$ 0.56 Income from continuing operations \$ 0.99 \$ 0.56 Income (loss) from discontinued operations \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES 1fe Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 299 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermed			
OPERATING INCOME 41 17 Net interest and other expense (income) (6) 10 Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 8 61 10 Income tax expense (benefit) - (24) INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 56 32 DILUTED EARNINGS PER SHARE 8 0.99 0.56 Income from continuing operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES 16 15 Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 33 28 Intermediates & Solvents 33 28 Intersegme			_
Net interest and other expense (income) (6) 10 Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 61 10 BEFORE INCOME TAXES 61 10 Income tax expense (benefit) - (24) INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 56 \$ 32 DILUTED EARNINGS PER SHARE Tolate the company of the company	· ·	+ +	17
Net income on divestitures 14 3 INCOME FROM CONTINUING OPERATIONS 6 1 0 Income tax expense (benefit) - (24) INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 56 \$ 32 DILUTED EARNINGS PER SHARE Income from continuing operations (0.08) (0.03) Net income \$ 0.99 \$ 0.56 Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 231 213 Intermediates & Solvents 33 28 Intersegment Sales			
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 61 10 10 10 10 10 10 10		* *	
BEFORE INCOME TAXES 61 10 Income tax expense (benefit) - (24) INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 56 \$ 32 DILUTED EARNINGS PER SHARE *** 0.99 \$ 0.56 Income from continuing operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 34 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales 6 552 5533		<u></u>	
Income tax expense (benefit)		61	10
INCOME FROM CONTINUING OPERATIONS 61 34 Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 56 \$ 32 DILUTED EARNINGS PER SHARE Income from continuing operations \$ 0.99 \$ 0.56 Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)		-	
Loss from discontinued operations (net of income taxes) (5) (2) NET INCOME \$ 56 32 DILUTED EARNINGS PER SHARE Income from continuing operations \$ 0.99 0.56 Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES 170 155 Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)	· · · · · · · · · · · · · · · · · · ·	61	
NET INCOME \$ 56 \$ 32 DILUTED EARNINGS PER SHARE Income from continuing operations \$ 0.99 \$ 0.56 Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)			
DILUTED EARNINGS PER SHARE Income from continuing operations Income (loss) from discontinued operations Net income \$ 0.99 \$ 0.56 (0.03) (0	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
Income from continuing operations \$ 0.99 \$ 0.56 Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)		<u>Ψ 33</u>	Ψ 02
Income from continuing operations \$ 0.99 \$ 0.56 Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)	DILLITED EADNINGS DED SHADE		
Income (loss) from discontinued operations (0.08) (0.03) Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)		Φ 0 00	¢ 0.56
Net income \$ 0.91 \$ 0.53 AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)			•
AVERAGE DILUTED COMMON SHARES OUTSTANDING 61 61 SALES Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)	·		
SALES Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)	Net income	<u>φ 0.91</u>	φ 0.55
Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)	AVERAGE DILUTED COMMON SHARES OUTSTANDING	61	61
Life Sciences 170 155 Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)	SALES		
Personal Care and Household 126 137 Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS) \$ 552 \$ 533		170	155
Consumer Specialties 296 292 Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS)			
Specialty Additives 147 139 Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS) \$ 552 \$ 533			
Performance Adhesives 84 74 Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - OPERATING INCOME (LOSS) \$ 552 \$ 533	<u>.</u>		
Industrial Specialties 231 213 Intermediates & Solvents 33 28 Intersegment Sales (8) - S 552 \$ 533 OPERATING INCOME (LOSS) *** ***			
Intermediates & Solvents 33 28 Intersegment Sales (8) - \$ 552 \$ 533 OPERATING INCOME (LOSS)			
Intersegment Sales	•		
\$ 552 \$ 533 OPERATING INCOME (LOSS)			-
OPERATING INCOME (LOSS)	moreognem balos		\$ 533
		<u>Ψ 302</u>	Ψ 000
	OPERATING INCOME (LOSS)		
		20	22
Personal Care and Household 15 11			
Consumer Specialties 44 33		* *	and the second s
Specialty Additives 2 9			
•			
()			(12)
	Unallocated and other		(23)
<u>\$ 41</u> <u>\$ 17</u>		<u>\$ 41</u>	<u>\$ 17</u>

Ashland Global Holdings Inc. and Consolidated Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS (In millions - preliminary and unaudited)

	Dece	ember 31 2020	Sep	tember 30 2020
ASSETS		•	•	•
Current assets				
Cash and cash equivalents	\$	335	\$	454
Accounts receivable		409		471
Inventories		537		529
Other assets		100		87
Held for sale		<u>-</u>		6
Total current assets		1,381		1,547
Noncurrent assets				
Property, plant and equipment				
Cost		3,310		3,265
Accumulated depreciation		1,748		1,700
Net property, plant and equipment		1,562		1,565
Goodwill		1,792		1,758
Intangibles		1,001		1,013
Operating lease assets, net		137		137
Restricted investments		316		301
Asbestos insurance receivable		130		136
Deferred income taxes		26		26
Other assets		397		394
Total noncurrent assets		5,361		5,330
Total assets	\$	6,742	\$	6,877
LIABILITIES AND EQUITY				
Current liabilities				
Short-term debt	\$	93	\$	280
Trade and other payables		217		233
Accrued expenses and other liabilities		252		277
Current operating lease obligations		23		23
Total current liabilities		585	-	813
Noncurrent liabilities				
Long-term debt		1,601		1,573
Asbestos litigation reserve		498		[,] 513
Deferred income taxes		222		229
Employee benefit obligations		157		157
Operating lease obligations		124		124
Other liabilities		433		432
Total noncurrent liabilities		3,035		3,028
Stockholders' equity		3,122		3,036
Total liabilities and stockholders' equity	\$	6,742	\$	6,877

Three months ended December 31

		Decem	ber 31	
		2020		2019
CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES				
FROM CONTINUING OPERATIONS				
Net income (loss)	\$	56	\$	32
Loss from discontinued operations (net of taxes)		5		2
Adjustments to reconcile income from continuing operations to				
cash flows from operating activities				
Depreciation and amortization		62		61
Original issue discount and debt issuance cost amortization		1		2
Deferred income taxes		(5)		(12)
Gain from sales of property and equipment		(4)		-
Stock based compensation expense		4		4
Income from restricted investments		(23)		(13)
Net income on divestitures		(14)		-
Impairments		9		-
Pension contributions		(2)		(1)
Change in operating assets and liabilities (a)		17		(109)
Total cash flows provided (used) by operating activities from continuing operations		106		(34)
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES				, ,
FROM CONTINUING OPERATIONS				
Additions to property, plant and equipment		(30)		(29)
Proceeds from disposal of property, plant and equipment		` 5 [°]		` -
Proceeds from sale or restructuring of operations		14		-
Net purchase of funds restricted for specific transactions		(1)		(1)
Reimbursements from restricted investments		`8 [']		10
Proceeds from sale of securities		42		4
Purchases of securities		(42)		(4)
Total cash flows used by investing activities from continuing operations		(4)		(20)
CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES		(.,		(20)
FROM CONTINUING OPERATIONS				
Proceeds from (repayment of) short-term debt		(187)		14
Cash dividends paid		(17)		(16)
Stock based compensation employee withholding taxes paid in cash		(3)		(5)
Total cash flows used by financing activities from continuing operations		(207)		(7)
CASH PROVIDED (USED) BY CONTINUING OPERATIONS		(105)	-	(61)
Cash provided (used) by discontinued operations		(100)		(01)
Operating cash flows		(14)		(17)
Investing cash flows		(3)		2
Effect of currency exchange rate changes on cash and cash equivalents		3		1
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-	(119)		(75)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		454	-	232
CASH AND CASH EQUIVALENTS - END OF PERIOD	\$	335	\$	157
CASH AND CASH EQUIVALENTS - END OF PERIOD	Φ	333	Φ	137
DEPOSITION AND AMORTIZATION				
DEPRECIATION AND AMORTIZATION		40		4.5
Life Sciences		16		15
Personal Care and Household		19		19
Consumer Specialties		35		34
Specialty Additives		21		20
Performance Adhesives		3		4
Industrial Specialties		24		24
Intermediates & Solvents		3		3
Unallocated and other		-		-
	\$	62	\$	61

⁽a) Excludes changes resulting from operations acquired or sold.

	Three months ende December 31							
Adjusted EBITDA - Ashland Global Holdings Inc.	2	020	2	019				
Net income	\$	56	\$	32				
Income tax expense (benefit)		-		(24)				
Net interest and other expense (income)		(6)		10				
Depreciation and amortization		62		61				
EBITDA	•	112		79				
Loss from discontinued operations (net of taxes)		5		2				
Net income on divestitures key items (see Table 5)		(14)		-				
Operating key items (see Table 5)		21		7				
Adjusted EBITDA	\$	124	\$	88				
Life Sciences		00	•	00				
Operating income	\$	29	\$	22				
Add:		40		4.5				
Depreciation and amortization	Φ.	16		15				
Adjusted EBITDA	<u>\$</u>	45	\$	37				
Personal Care and Household								
Operating income	\$	15	\$	11				
Add:								
Depreciation and amortization		19		19				
Adjusted EBITDA	\$	34	\$	30				
Adjusted EBITDA - Consumer Specialties Total								
Operating income	\$	44	\$	33				
Add:	•		•					
Depreciation and amortization		35		34				
Adjusted EBITDA	\$	79	\$	67				
	<u></u>		<u> </u>					

		Three month Decemb 2020		
Specialty Additives	_			
Operating income	\$	2	\$	9
Add:				
Depreciation and amortization		21		20
Operating key items (see Table 5)		9		
Adjusted EBITDA	\$	32	\$	29
Performance Adhesives				
Operating income	\$	20	\$	10
Add:				
Depreciation and amortization		3		4
Adjusted EBITDA	<u>\$</u>	23	\$	14
Adjusted EBITDA - Industrial Specialties Total				
Operating income	\$	22	\$	19
Add:				
Depreciation and amortization		24		24
Operating key items (see Table 5)		9		
Adjusted EBITDA	<u>\$</u>	<u>55</u>	\$	43
Adjusted EBITDA - Intermediates and Solvents				
Operating income	\$	2	\$	(12)
Add:				
Depreciation and amortization		3	_	3
Adjusted EBITDA	\$	5	\$	(9)

Ashland Global Holdings Inc. and Consolidated Subsidiaries SEGMENT COMPONENTS OF KEY ITEMS FOR APPLICABLE INCOME STATEMENT CAPTIONS

(In millions - preliminary and unaudited)

							Th	ee Mon	ths Ended	Decen	nber 31, 2	020						
		ife nces	Ca aı	sonal are nd sehold		umer ialties	Spec Addi		Performa Adhesiv		Indus Specia		Interme			ocated Other	Tot	al
OPERATING INCOME (LOSS)		11000	11000	onoid	Орос	unioo	71001	1700	71011001	•00	Ороск		una oc	- Tronto				<u> </u>
Operating key items:																		
Restructuring, separation and other costs	\$	-	\$	-	\$	-	\$	- (0)	\$	-	\$	-	\$	-	\$	(12)	\$	(12)
Capital project impairment All other operating income (loss)		29		15		44		(9) 11		20		(9) 31		2		(1 <u>5</u>)		(9) 62
Operating income (loss)		29	-	15		44		2	-	20	-	22	-	2		(27)		41
operating mounte (1888)								_						_		(=.)		• •
NET INTEREST AND OTHER EXPENSE (INCOME)																		
Key items																(18)		(18)
All other net interest and other expense (income)																12		12
																(6)		(6)
NET INCOME ON DIVESTITURES																14		4.4
Key items																14		14
INCOME TAX EXPENSE (BENEFIT)																		
Tax effect of key items (a)																4		4
Tax specific key items (b)																(13)		(13)
All other income tax expense (benefit)																9		9
INCOME (LOSS) FROM CONTINUING OPERATIONS	\$	29	\$	15	\$	44	\$	2	\$	20	\$	22	\$	2	\$	(7)	\$	61
	*		*				*		*	_ <u>=</u>	*		*		<u> </u>		<u> </u>	<u> </u>
							Thi	ee Mont	hs Ended	Decen	-104 0	040						
					4.0						nber 31, z	פוט						
		٠		sonal		•					nber 31, 2	019	:					
	Li	fe		are	Cons	umer	• •	•	Performa	•	Indus	•	Interme	ediates	Unall	ocated		
	Li Scie		Ca aı	are		umer alties	Spec Addi	ialty	Performa Adhesis	ance		trial		ediates olvents		ocated Other	Tot	al
OPERATING INCOME (LOSS)			Ca aı	are nd			Spec	ialty		ance	Indus	trial					Tot	al
Operating key items:	Scie		Ca aı <u>Hous</u>	are nd	Spec	alties	Spec Addi	ialty	_Adhesiv	ance	Indus Specia	trial Ilties	and So	olvents	_ & (Other		
Operating key items: Restructuring, separation and other costs		nces_	Ca aı	are nd ehold -		alties_	Spec	ialty ives		ance ves_	Indus	trial Ilties		olvents_		<u>Other</u> (7)		(7)
Operating key items:	Scie		Ca aı <u>Hous</u>	are nd	Spec	alties	Spec Addi	ialty	_Adhesiv	ance	Indus Specia	trial Ilties	and So	olvents	_ & (Other		
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss)	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16)		(7) 24
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME)	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23)		(7) 24 17
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23)		(7) 24 17
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME)	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23) (9) 19		(7) 24 17 (9) 19
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23)		(7) 24 17
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23) (9) 19		(7) 24 17 (9) 19
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense (income) NET INCOME ON DIVESTITURES	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23) (9) 19 10		(7) 24 17 (9) 19
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense (income) NET INCOME ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT)	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23) (9) 19 10		(7) 24 17 (9) 19 10
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense (income) NET INCOME ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT) Tax effect of key items (a)	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23) (9) 19 10 3		(7) 24 17 (9) 19 10 3
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense (income) NET INCOME ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT)	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23) (9) 19 10		(7) 24 17 (9) 19 10
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense (income) NET INCOME ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT) Tax effect of key items (a) Tax specific key items (b) All other income tax expense (benefit)	Scie	22 22 22	Ca ai Hous	ere nd <u>lehold</u> - 11 11	<u>Spec</u>	33 33 33	Spec Addi	ialty ives	Adhesiv \$	- 10 10	Indus Specia	trial Ilties 19 19	and So	- (12) (12)	* * * * * * * * * * * * * * * * * * *	(7) (16) (23) (9) 19 10 3 1 (25) - (24)		(7) 24 17 (9) 19 10 3 1 (25) (24)
Operating key items: Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense (income) NET INCOME ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT) Tax effect of key items (a) Tax specific key items (b)	Scie	nces - 22	Ca aı <u>Hous</u>	ere nd sehold - 11	Spec	alties - 33	Spec Addi	ialty ives	_Adhesiv	ance ves - 10	Indus Specia	trial Ilties	and So	- (12)	_ & ((7) (16) (23) (9) 19 10 3 1 (25)		(7) 24 17 (9) 19 10 3

Represents the tax effect of the key items that are previously identified above.

Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. See Table 7 for additional information.

RECONCILIATION OF CERTAIN NON-GAAP DATA

(In millions - preliminary and unaudited)

	Three months ended December 31							
Free cash flows (a)	2	020	2	019				
Total cash flows provided by operating activities from continuing operations	\$	106	\$	(34)				
Adjustments:								
Additions to property, plant and equipment		(30)		(29)				
Free cash flows (a) (b)	\$	76	\$	(63)				

Free cash flow is defined as cash flows provided (used) by operating activities less additions to property, plant and equipment and other items Ashland has deemed non-operational (if applicable).

Includes \$14 million and \$6 million of restructuring payments for the three months ended December 31, 2020 and 2019, respectively. (a)

⁽b)

	rnree months ended							
	December 31							
Adjusted operating income	202	0	2	019				
Operating income (as reported)	\$	41	\$	17				
Key items, before tax:								
Restructuring, separation and other costs		12		7				
Capital project impairment		9		<u>-</u>				
Adjusted operating income (non-GAAP)	\$	62	\$	24				

RECONCILIATION OF CERTAIN NON-GAAP DATA

(In millions except per share data - preliminary and unaudited)

	Т	ded		
	2020		2	019
Income from continuing operations (as reported)	\$	61	\$	34
Key items, before tax:				
Restructuring, separation and other costs		12		7
Capital project impairment		9		-
Unrealized gain on securities		(18)		(9)
Net gain on acquisitions and divestitures		(14)		
Key items, before tax		(11)		(2)
Tax effect of key items (a)		4		1
Key items, after tax		(7)		(1)
Tax specific key items:				
Restructuring and separation activity		(13)		-
Other tax reform related activity				(25)
Tax specific key items (b)		(13)		(25)
Total key items		(20)		(26)
Adjusted income from continuing operations (non-GAAP)	\$	41	\$	8
Amortization expense adjustment (net of tax) (c)		17		17
Adjusted income from continuing operations (non-GAAP) excluding intangibles amortization expense	\$	58	\$	25

Represents the tax effect of the key items that are previously identified above.

Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

- Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

- Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2020.

Amortization expense adjustment (net of tax) tax rates were 21% and 20% for the three months ended December 31, 2020 and 2019, respectively.

RECONCILIATION OF CERTAIN NON-GAAP DATA

(In millions except per share data - preliminary and unaudited)

		ded			
		2020	2019		
Diluted EPS from continuing operations (as reported)	\$	0.99	\$	0.56	
Key items, before tax:					
Restructuring, separation and other costs		0.18		0.12	
Capital project impairment		0.16		-	
Unrealized gain on securities		(0.29)		(0.15)	
Net gain on acquisitions and divestitures		(0.23)		-	
Key items, before tax		(0.18)		(0.03)	
Tax effect of key items (a)		0.07		0.02	
Key items, after tax		(0.11)		(0.01)	
Tax specific key items:					
Restructuring and separation activity		(0.22)		-	
Other tax reform related activity		-		(0.42)	
Tax specific key items (b)		(0.22)		(0.42)	
Total key items		(0.33)		(0.43)	
Adjusted diluted EPS from continuing operations (non-GAAP)	\$	0.66	\$	0.13	
Amortization expense adjustment (net of tax) (c)		0.28		0.28	
Adjusted diluted EPS from continuing operations (non-GAAP) excluding intangibles amortization expense	\$	0.94	\$	0.41	

Represents the tax effect of the key items that are previously identified above.

Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2020.

Amortization expense adjustment (net of tax) tax rates were 21% and 20% for the three months ended December 31, 2020 and 2019, respectively.